Toxicity of targeted anticancer treatments on the liver in myeloproliferative neoplasms.

Autor:	Purwar S; Department of Internal Medicine, Grant Government Medical College, Mumbai 400008, Maharashtra, India., Fatima A; Department of Internal Medicine, Pandit Jawaharlal Nehru Memorial Medical College, Raipur 492001, Chhattisgarh, India., Bhattacharyya H; Department of Community & Family Medicine, AIIMS Guwahati, Assam 781101, India., Simhachalam Kutikuppala LV; Department of General Surgery, Dr NTR University of Health Sciences, Vijayawada 521104, Andhra Pradesh, India., Cozma MA; Faculty of Medicine, 'Carol Davila' University of Medicine and Pharmacy, Bucharest 050474, Romania.; Department of Gastroenterology, Colentina Clinical Hospital, Bucharest 020125, Romania., Srichawla BS; Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01655, United States., Komer L; Department of Psychiatry, University of Toronto, Toronto M5G 1V7, Ontario, Canada., Nurani KM; Faculty of Health Sciences, University of Nairobi, Nairobi 30197-00100, Kenya., Găman MA; Faculty of Medicine, 'Carol Davila' University of Medicine and Pharmacy, Bucharest 050474, Romania.; Department of Hematology, Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest 022328, Romania. mihneagaman@yahoo.com.
Jazyk:	angličtina
Zdroj:	World journal of hepatology [World J Hepatol] 2023 Sep 27; Vol. 15 (9), pp. 1021-1032.
DOI:	10.4254/wjh.v15.i9.1021
Abstrakt:	The liver has a central role in metabolism, therefore, it is susceptible to harmful effects of ingested medications (drugs, herbs, and nutritional supplements). Drug-induced liver injury (DILI) comprises a range of unexpected reactions that occur after exposure to various classes of medication. Even though most cases consist of mild, temporary elevations in liver enzyme markers, DILI can also manifest as acute liver failure in some patients and can be associated with mortality. Herein, we briefly review available data on DILI induced by targeted anticancer agents in managing classical myeloproliferative neoplasms: Chronic myeloid leukemia, polycythemia vera, essential thrombocythemia, and myelofibrosis. Competing Interests: Conflict-of-interest statement: The authors have no conflicts of interest to declare. (©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu